Drug Profile
Phentolamine - Ocuphire Pharma
Alternative Names: 0.75% phentolamine ophthalmic solution - Ocularis Pharma; 1% phentolamine mesylate - Ocularis Pharma; Nyxol; Phentolamine mesylate ophthalmic solution - Ocularis Pharma; RYZUMVILatest Information Update: 18 Mar 2024
Price :
$50
*
At a glance
- Originator Ocularis Pharma
- Developer Ocuphire Pharma
- Class Antiglaucomas; Erectile dysfunction therapies; Eye disorder therapies; Imidazoles; Peripheral vasodilators; Small molecules
- Mechanism of Action Alpha 1 adrenergic receptor antagonists; Alpha 2 adrenergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Registered Mydriasis
- Phase III Nyctalopia; Presbyopia
- Phase II Ocular hypertension; Open-angle glaucoma
Most Recent Events
- 08 Mar 2024 Ocuphire plans the phase III LYNX-2 study in Nyctalopia (Dim light vision disturbances) in USA in the first half of 2024
- 08 Mar 2024 Ocuphire Pharma plans to launch phentolamine for Mydriasis in USA in the H1 2024
- 04 Jan 2024 Ocuphire Pharma anticipates to submit regulatory applications in Nyctalopia